// App-Quantinova.ai

FRI0131 : SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE

Researchers

Presenter

  • P. Nash

Principal Investigators

  • A. Kavanaugh

  • M. H. Buch

  • B. Combe

  • L. Bessette

  • I. H. Song

  • Y. Song

  • J. Suboticki

  • R. Fleischmann

Medical Centers

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Lapeyronie Hospital, Montpellier I University, UMR , EA, Montpellier, France

  • Université Laval, Centre hospitalier de l’Université Laval, Quebec, Canada

  • Univ of Texas Southwestern, and Metroplex Research Center, Dallas, United States of America

Locations

  • Australia

  • United States

  • United Kingdom

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • Methotrexate

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved